Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA’s Gottlieb Eyes PBM Consolidation Impact on Generic Entry: CNBC

Reuters Staff  |  

NEW YORK (Reuters)—The head of the U.S. Food & Drug Administration Scott Gottlieb said on Wednesday that he was concerned about the impact of deals like the CVS Health purchase of Aetna Inc. on the ability of pharmaceutical companies to block the entry of cheaper copycat drugs.

As the pharmacy benefit managers and the drug supply chains consolidate, Gottlieb said, they are making it easier for pharmaceutical companies to block access to their drugs from the generic companies that are legally entitled to create cheaper copycat versions of the medicines.

ADVERTISEMENT
SCROLL TO CONTINUE

“We don’t have direct purview over it but we do have something to say about it and we’re going to be speaking to the PBMs about it,” Gottlieb said.

Cigna Corp. also agreed recently to buy pharmacy benefit manager Express Scripts Holding Inc.

ADVERTISEMENT
SCROLL TO CONTINUE

 

Related Articles

    Trump Chooses Gottlieb to Run FDA; Pharma Breathes Sigh of Relief

    WASHINGTON (Reuters)—U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, the White House said on Friday. If confirmed by the Senate, Gottlieb would be in charge of implementing Trump’s plan to dramatically cut regulations governing…

    U.S. FDA Chief Gottlieb Resigns

    WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs. The U.S. Department of Health and Human Services (HHS), which oversees the…

    FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs

    WASHINGTON (Reuters)—U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for “Kabuki drug-pricing constructs” that profit the industry at the expense of consumers. The comments, made at a conference organized by a leading U.S. health insurer lobbying group, stoked speculation over what steps the administration of…

    Generic-Drug Price Fixing: Is It Happening?

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…